GIANT BIOGENE (02367) dropped over 5% again, declining 5.33% to HK$50.6 with trading volume of HK$628 million as of press time. On the news front, the 2025 Double 11 e-commerce promotion has launched ahead of schedule.

Huatai Securities previously noted that despite facing certain external factors in Q2 2025, GIANT BIOGENE still achieved double growth in revenue and profit in the first half of the year, maintaining relatively stable profitability, demonstrating brand resilience and earnings stability. With the Double 11 peak season approaching, the company's brand promotion and influencer marketing activities are expected to gradually recover and drive accelerated H2 growth.

Notably, Huaxi Biology announced at the end of September that it had collaborated with the National Institute of Metrology and multiple third-party testing institutions to conduct testing on related products from relevant companies. The results showed that dozens of test reports indicated that the recombinant collagen protein content in the related products did not meet standards. Huaxi Biology stated that it "has submitted dozens of test reports to the National Medical Products Administration."

Analysts noted that Collagen Recovery underperformed during this year's 618 e-commerce promotion, and the market will closely watch the product's e-commerce sales performance during the Double 11 period.